Results
|
341.
|
|
|
342.
|
|
|
343.
|
|
|
344.
|
|
|
345.
|
|
|
346.
|
|
|
347.
|
Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. [electronic resource] by
- Hast, Bridgid E
- Cloer, Erica W
- Goldfarb, Dennis
- Li, Heng
- Siesser, Priscila F
- Yan, Feng
- Walter, Vonn
- Zheng, Ning
- Hayes, D Neil
- Major, Michael B
Producer: 20140415
In:
Cancer research vol. 74
Availability: No items available.
|
|
348.
|
|
|
349.
|
|
|
350.
|
|
|
351.
|
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. [electronic resource] by
- Lister, Adam
- Nedjadi, Taoufik
- Kitteringham, Neil R
- Campbell, Fiona
- Costello, Eithne
- Lloyd, Bryony
- Copple, Ian M
- Williams, Samantha
- Owen, Andrew
- Neoptolemos, John P
- Goldring, Chris E
- Park, B Kevin
Producer: 20110928
In:
Molecular cancer vol. 10
Availability: No items available.
|
|
352.
|
|
|
353.
|
|
|
354.
|
|
|
355.
|
Development of a High-Throughput Cul3-Keap1 Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for Identifying Nrf2 Activators. [electronic resource] by
- Poore, Derek D
- Hofmann, Glenn
- Wolfe, Lawrence A
- Qi, Hongwei
- Jiang, Ming
- Fischer, Michael
- Wu, Zining
- Sweitzer, Thomas D
- Chakravorty, Subhas
- Donovan, Brian
- Li, Hu
Producer: 20200327
In:
SLAS discovery : advancing life sciences R & D vol. 24
Availability: No items available.
|
|
356.
|
|
|
357.
|
|
|
358.
|
|
|
359.
|
|
|
360.
|
|